- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01955876
Fosrenol Post-marketing Surveillance in Japan
Drug Use Investigation of Fosrenol for Hyperphosphatemia With Chronic Kidney Disease Not on Dialysis
This study is a regulatory post-marketing surveillance in Japan and it is a local prospective and observational study of patients who have received Fosrenol.
The objective of this research is to collect information on the safety of Fosrenol after its launching, which means collecting information on adverse events, especially adverse events in the digestive system including constipation and serious adverse events, and adverse drug reactions when the drug is administered to the below-mentioned target patients for six months.
The secondary objective is to collect information on the safety of the drug when administered for more than six months, which means collecting information on the safety of the drug when administered for up to 12 months to the target patients who have already been treated with the drug for six months. And also if at the time of 12 months after administration of Lanthanum carbonate the dialysis is not conducted, extending its' administration will be continued until conduction of dialysis, or until Sept. 30, 2015. The efficacy of fosrenol is evaluated by observing the serum P(phosphorus) level and serum PTH (parathyroid hormone) level change.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Multiple Locations, Japan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients whom investigators have decided to treat with Lanthanum carbonate for the first time at the respective medical institutions. Those medical institutions have to understand the objective of this investigation and conclude a written contract with Bayer Yakuhin.
- The decision to treat patients with Lanthanum carbonate will be made independently by the investigator prior to study inclusion.
- Patients treated with Lanthanum carbonate in the indication "Hyperphosphatemia" with chronic kidney disease not on dialysis".
Exclusion Criteria:
- Patients who are contraindicated based on the product label.
- Patients who have been already treated with Fosrenol
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group 1
|
Patients treated with Fosrenol in daily clinical practice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence/number of episodes of adverse drug reactions and adverse events
Time Frame: 6 months after start of treatment with the drug
|
6 months after start of treatment with the drug
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence/number of episodes of adverse drug reactions and adverse events
Time Frame: until the conduction of dialysis after starting the treatment with Lanthanum carbonate(Maximum 2 years)
|
until the conduction of dialysis after starting the treatment with Lanthanum carbonate(Maximum 2 years)
|
Adverse drug event rate related to the digestive system
Time Frame: until the conduction of dialysis(Maximum 2 years)
|
until the conduction of dialysis(Maximum 2 years)
|
Incidence/number of episodes of adverse events for 6, 12 months ,and from month 13 to the conduction of dialysis after starting the treatment with Lanthanum carbonate.
Time Frame: until the conduction of dialysis(Maximum 2 years)
|
until the conduction of dialysis(Maximum 2 years)
|
Incidence/number of episodes of adverse drug reactions for 6, 12 months ,and from month 13 to the conduction of dialysis after starting the treatment with Lanthanum carbonate according to patient characteristics and treatment with Lanthanum carbonate.
Time Frame: until the conduction of dialysis(Maximum 2 years)
|
until the conduction of dialysis(Maximum 2 years)
|
Serum P level for six months after start of treatment with the drug in comparison with baseline (at the time of start of treatment with fosrenol)
Time Frame: 6 months after start of treatment with the drug
|
6 months after start of treatment with the drug
|
Serum intact PTH level for six months after start of treatment with the drug in comparison with baseline
Time Frame: 6 months after start of treatment with the drug
|
6 months after start of treatment with the drug
|
Serum P level at 12 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Fosrenol).
Time Frame: 12 months
|
12 months
|
Serum P level at the conduction of dialysis from 13 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Fosrenol).
Time Frame: until the conduction of dialysis(Maximum 2 years)
|
until the conduction of dialysis(Maximum 2 years)
|
Serum intact PTH level at 12 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Lanthanum carbonate).
Time Frame: 12 months
|
12 months
|
Serum intact PTH level at the conduction of dialysis from 13 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Lanthanum carbonate).
Time Frame: until the conduction of dialysis(Maximum 2 years)
|
until the conduction of dialysis(Maximum 2 years)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16626
- FOSRENOL-PRED (OTHER: company internal)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperphosphatemia
-
Taisho Pharmaceutical Co., Ltd.CompletedHyperphosphatemia Patients on HemodialysisJapan
-
Kissei Pharmaceutical Co., Ltd.CompletedHemodialysis Patients With HyperphosphatemiaJapan
-
Kyowa Kirin Korea Co., Ltd.RecruitingHyperphosphatemiaKorea, Republic of
-
Kyowa Kirin Co., Ltd.CompletedHyperphosphatemiaJapan
-
Kyowa Kirin Co., Ltd.CompletedHyperphosphatemiaJapan
-
BayerCompleted
-
Washington University School of MedicineCompletedHyperphosphatemiaUnited States
-
Fresenius Medical Care North AmericaRenal Research InstituteCompleted
-
BayerCompletedHyperphosphatemia | DialysisJapan
Clinical Trials on Lanthanum Carbonate (Fosrenol, BAY77-1931)
-
BayerCompleted
-
BayerShireCompleted
-
BayerCompletedHyperphosphatemiaJapan
-
BayerCompleted
-
BayerCompleted
-
BayerCompletedHyperphosphatemia | DialysisJapan
-
ShireCompletedEnd Stage Renal DiseaseUnited States
-
Lundquist Institute for Biomedical Innovation at...CompletedEnd-stage Renal Disease | Chronic Kidney Failure | Disorders Associated With Peritoneal DialysisUnited States